Cargando…
Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer
In the latest years, some drugs have been approved by European Medicines Agency (EMA) and/or the US Food and Drug Administration (FDA) for the treatment of patients with advanced non-small cell lung cancer (NSCLC), particularly for the treatment of those who have no targeted gene mutations or who ha...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6699593/ https://www.ncbi.nlm.nih.gov/pubmed/31616186 http://dx.doi.org/10.2147/CMAR.S212238 |